RESUMEN
Objective: To investigate the effect of siRNA targeting inhibition of α-enolase (ENO1) combined with paclitaxel on the proliferation, invasion and apoptosis of hepatocellular carcinoma SK-HEP-1 cell and its mechanism. Methods: siRNA-ENO1 (siRNA-ENO1 group) and siRNA-negative control (siRNA-NC group) were transfected into SK-HEP-1 cells in vitro, the untransfected SK-HEP-1 cells were used as the control group, and the transfection effect was detected by real-time fluorescent quantitative polymerase chain reaction and western blotting. After SK-HEP-1 cells were treated with 0, 2.5, 5, 10, 20 and 40 µg/L paclitaxel for 48 hours, the cell survival rate was measured by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H tetrazolium bromide (MTT) method and the semi inhibitory concentration of paclitaxel was calculated. SK-HEP-1 cells transfected with siRNA-ENO1 or siRNA-NC were treated with 10 µg/L paclitaxel as paclitaxel+ siRNA-ENO1 group and paclitaxel+ siRNA-NC group. The proliferation, clonogenesis, invasion and apoptosis of siRNA-NC group, siRNA-ENO1 group, paclitaxel+ siRNA-ENO1 group and paclitaxel+ siRNA-NC group were detected by MTT, clonogenesis, Transwell chamber and flow cytometry respectively. The expression levels of the phosphorylation of phosphatidylinositol-3-kinase (p-PI3K), p-protein kinase B (Akt) and proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 9 (MMP-9) and B lymphocytoma-2 gene (Bcl-2) were detected by western blotting. Results: Compared with the control group (1.00±0.00 and 0.69±0.04, respectively), the expression levels of ENO1 mRNA and protein (0.25±0.03 and 0.23±0.02, respectively) in siRNA-ENO1 group decreased significantly (P<0.05), but there were no significant differences in the expression levels of ENO1 mRNA and protein in siRNA-NC group (P>0.05). Compared without treatment group [(100.00±0.00)%, P<0.05], the survival rates of SK-HEP-1 cells treated with 2.5, 5, 10, 20 and 40 µg/L paclitaxel [(88.65±6.46)%, (72.36±6.08)%, (60.48±4.23)%, (38.52±3.56)% and (20.75±2.32)%, respectively] decreased significantly (P<0.05), and the semi inhibitory concentration of paclitaxel was 13.26 µg/L. The cell survival rate and clone formation rate of siRNA-ENO1 group [(68.86±5.12)% and (18.12±2.25)%, respectively] were lower than those of siRNA-NC group [(100.00±0.00)% and (29.65±3.06)%, respectively, P<0.05]. The cell survival rate and clone formation rate of the paclitaxel+ siRNA-ENO1 group [(43.28±2.64)% and (8.72±0.52)%, respectively] were significantly different from those of the paclitaxel+ siRNA-NC group [(61.75±5.06)% and (13.48±2.16)%, respectively, P<0.05] and siRNA-ENO1 groups [(68.86±5.12)% and (18.12±2.25)%, respectively, P<0.05]. Cell invasion number in paclitaxel+ siRNA-ENO1 group (23.64±2.12) was lower than that in siRNA-ENO1 group and paclitaxel+ siRNA-NC group (42.16±2.75 and 37.35±2.42, respectively, P<0.05). The apoptosis rates of paclitaxel+ siRNA-NC group and siRNA-ENO1 group [(17.49±1.35)% and (15.29±1.50)%, respectively] were higher than that of siRNA-NC group [(7.21±0.70)%, P<0.05]. The apoptosis rate in the paclitaxel+ siRNA-ENO1 group [(24.59±2.40)%] was higher than those in the paclitaxel+ siRNA-NC group and siRNA-ENO1 group [(17.49±1.35)% and (15.29±1.50)%, respectively, P<0.05]. The expression levels of ENO1, PI3K/Akt signaling pathway related proteins including p-PI3K and p-Akt and the expression levels of PCNA, MMP-9 and Bcl-2 in siRNA-ENO1 group and paclitaxel+ siRNA-NC group were lower than those in siRNA-NC group (P<0.05). The expression levels of ENO1, p-PI3K, p-Akt, PCNA, MMP-9 and Bcl-2 in paclitaxel+ siRNA-ENO1 group were lower than those in siRNA-ENO1 group or paclitaxel+ siRNA-NC group (P<0.05). Conclusion: siRNA targeting inhibition of ENO1 expression can enhance the inhibitory effect of paclitaxel on proliferation, invasion and apoptosis of SK-HEP-1 cells, and its mechanism may be related to the inhibition of PI3K/AKT signaling pathway.
Asunto(s)
Carcinoma Hepatocelular , Neoplasias Hepáticas , Paclitaxel , Fosfopiruvato Hidratasa , ARN Interferente Pequeño , Apoptosis , Carcinoma Hepatocelular/genética , Línea Celular Tumoral , Proliferación Celular , Humanos , Neoplasias Hepáticas/genética , Invasividad Neoplásica , Paclitaxel/farmacología , Fosfatidilinositol 3-Quinasas , Fosfopiruvato Hidratasa/genética , ARN Interferente Pequeño/genéticaRESUMEN
OBJECTIVE: Ribosomal protein S15A (RPS15A) has been implicated in tumorigenesis, but its role in colorectal cancer (CRC) is not fully studied. The objective of this study was to investigate the role of RPS15A in CRC carcinogenesis. PATIENTS AND METHODS: RBSP15A expression was detected in 120 colorectal adenocarcinoma biopsies by immunohistological staining, and we examined the association of RSP15A expression with clinicopathological outcomes. We generated RPS15A stable knockdown CRC cell lines using shRNAs and assessed cell proliferation by MTT assays, clonogenicity by colony formation assays, and apoptosis and cell cycle arrest by flow cytometric analyses. A mouse tumor xenograft model was used to confirm the influence of RPS15A expression on CRC in vivo. RESULTS: RPS15A expression was predictive for poor disease-free survival. Knockdown of RPS15A expression significantly inhibited cell proliferation and colony formation and augmented apoptosis in both the RKO and SW620 CRC cell lines. Moreover, RPS15A knockdown arrested RKO cells at the G2/M phase and SW620 cells at the G0/G1 phase. KEGG pathway analysis of 785 genes differentially expressed between wild-type and shRPS15A RKO cells showed enrichment for the pathway in cancer and MAPK signaling pathway KEGG terms. RPS15A knockdown induced apoptosis via regulation of BIRC3, p38 MAPK, and Chk1. Consistently, RPS15A knockdown significantly impaired the growth of subcutaneous CRC xenografts in nude mice. CONCLUSIONS: These results indicate that RPS15A is a novel, potentially oncogenic gene involved in colorectal carcinogenesis. RPS15A knockdown may be an attractive strategy for treating CRC with gene therapy.
Asunto(s)
Adenocarcinoma/genética , Proteína 3 que Contiene Repeticiones IAP de Baculovirus/genética , Quinasa 1 Reguladora del Ciclo Celular (Checkpoint 1)/metabolismo , Neoplasias Colorrectales/genética , Proteínas Ribosómicas/genética , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo , Adenocarcinoma/mortalidad , Adenocarcinoma/patología , Animales , Apoptosis/genética , Puntos de Control del Ciclo Celular/genética , Línea Celular Tumoral , Proliferación Celular/genética , Neoplasias Colorrectales/mortalidad , Neoplasias Colorrectales/patología , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Estimación de Kaplan-Meier , Masculino , Ratones Desnudos , Persona de Mediana EdadRESUMEN
OBJECTIVE: The autophagy pathway is a critical process in Mycobacterium tuberculosis infection, and can be regulated by uncoordinated 51-like kinase 1 (ULK1). We investigated the associations between single-nucleotide polymorphisms (SNPs) in ULK1 and risk of tuberculosis (TB) in a Chinese Han population. DESIGN: We recruited 380 pulmonary tuberculosis (PTB) cases, 242 extra-pulmonary tuberculosis (EPTB) cases and 606 healthy controls from a Chinese Han population and sequenced ULK1. Five SNPs in ULK1 were selected to investigate the correlations between ULK1 polymorphisms and TB susceptibility. RESULTS: The rs7138581 C allele was associated with a reduced risk of PTB (P = 0.001), whereas the rs9481 A allele was associated with an increased risk (P = 0.025). The rs7138581 CG genotype was significantly associated with a low risk of PTB, with a higher PTB disease severity in clinical parameters. Estimation of haplotype frequencies in ULK1 revealed a protective haplotype CCGAA (P = 0.007) and a potential risk haplotype TGAAA (P = 0.010) for PTB. CONCLUSION: These results demonstrated that ULK1 polymorphisms have significant associations with susceptibility to PTB.
Asunto(s)
Homólogo de la Proteína 1 Relacionada con la Autofagia/genética , Predisposición Genética a la Enfermedad , Péptidos y Proteínas de Señalización Intracelular/genética , Tuberculosis Pulmonar/epidemiología , Tuberculosis/epidemiología , Adulto , Pueblo Asiatico/genética , Autofagia/genética , Estudios de Casos y Controles , Femenino , Genotipo , Haplotipos , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Tuberculosis/genética , Tuberculosis Pulmonar/genética , Adulto JovenRESUMEN
OBJECTIVE: To evaluate the interference in Triiodothyronine (T3) analysis on the Immuno 1 Analyzer. METHODS: We analyzed 686 samples for T3 using the Miles Technicon Immuno 1 Analyzer. We compared the results of 318 samples with those given by radioimmunoassay (RIA) and the remaining 368 results with those given by the Ciba-Corning ACS 180 analyzer. RESULTS: On the Immuno 1 correlated with those by RIA or chemiluminescence immunoassay. However, results on eight patients by the Immuno 1 method were anomalously elevated. We attempted to find and eliminate the cause of the interference on the Immuno 1. Although the method uses an alkaline phosphatase labelled T3 analog and fluoresceinated monoclonal antibody, serum binding of fluorescein or alkaline phosphatase did not appear to be the major causes of the interference. Ethanol extraction of samples followed by reconstitution in zero calibrator was the only reliable way to eliminate the interference. CONCLUSION: The Immuno 1 assay was more prone to interference than other methods. Until it is reformulated, we recommend that users assay ethanol extracts of samples with unexpectedly high T3.
Asunto(s)
Inmunoensayo/instrumentación , Triyodotironina/análisis , Triyodotironina/inmunología , Fosfatasa Alcalina/química , Animales , Anticuerpos/química , Estudios de Evaluación como Asunto , Reacciones Falso Positivas , Humanos , Hidrocortisona/química , Hidrocortisona/inmunología , Inmunoensayo/métodos , Inmunoensayo/normas , Indicadores y Reactivos , Radioisótopos de Yodo , Ratones , Tirotropina/química , Triyodotironina/químicaRESUMEN
The measurement of creatinine by two Jaffé-based procedures is described. In comparing the Beckman Creatinine Analyzer II and the Greiner Selective Analyzer GSA IID, better between-day precision was observed with the former. Percentage recovery of creatinine added to serum was quantitative for the Beckman Creatinine Analyzer II and 92-95% for the Greiner Selective Analyzer. The Greiner Selective Analyzer employs a serum blank and for this reason interference produced by pseudo-Jaffé chromogens in the measurement of creatinine was far less significant than the corresponding interferences observed with the Beckman Creatinine Analyzer II. Comparison of results obtained on 100 sera and 40 urine samples provided correlation coefficients of 0.998 and 0.997 respectively.